Cogent submits New Drug Application for bezuclastinib in nonadvanced SM
Cogent Biosciences submitted a New Drug Application to the FDA for bezuclastinib in non-advanced SM, with future submissions planned in 2026.
Cogent Biosciences submitted a New Drug Application to the FDA for bezuclastinib in non-advanced SM, with future submissions planned in 2026.
Drugs may induce hypersensitivity reactions in SM, requiring clinical caution.
A recent case report describes the rare reoccurrence of mastocytosis in an adult patient 40 years after a childhood diagnosis.
A study proposed two scoring systems that were found to be effective in assessing gastrointestinal symptoms in patients with SM.
There is a strong link between mastocytosis and serious allergic reactions to insect stings, especially from insects like bees and wasps.
A particular form of spinal fracture was found to be more common in indolent systemic mastocytosis compared with primary osteoporosis.
A group of experts in anaphylaxis offered recommendations for epinephrin use in different patient populations, including those with SM.
A young girl with severe systemic mastocytosis (SM) experienced recurrent fainting episodes, initially misdiagnosed as reflex syncope.
When children develop small, uniform reddish-brown spots or bumps on their back, belly, or limbs, it may be a sign of SM.
In people with SM, mast cells may contribute to anemia by breaking down red blood cells.